Bone Metabolism and Immune Regulation of Statins in Craniofacial Defects Regeneration

doi:10.13701/j.cnki.kqyxyj.2021.07.003

Abstract

Abstract: Statins are known for their beneficial effects on lowering cholesterol, which contribute to the treatment of cardiovascular diseases. In recent years, more and more experimental results have demonstrated that statins modulate inflammation, immune response, bone metabolism, and bacterial clearance through several pathways. Local delivery systems combining an osteoconductive biomaterial with statins is a popular approach in the regeneration of craniofacial defects. In this paper we review the direct and indirect mechanism of statins by affecting the immune system in bone metabolism.

Key words: statins, bone metabolism, bone regeneration, osteoimmunology

HUANG Jiaqian, MA Guowu. Bone Metabolism and Immune Regulation of Statins in Craniofacial Defects Regeneration[J]. Journal of Oral Science Research, 2021, 37(7): 592-594.

References

[1] Martin V, Bettencourt A. Bone regeneration: Biomaterials as local delivery systems with improved osteoinductive properties [J]. Mater Sci Eng C Mater Biol Appl, 2018, 82:363-371.
[2] Shah SR, Werlang CA, Kasper FK, et al. Novel applications of statins for bone regeneration [J]. Natl Sci Rev, 2015, 2(1):85-99.
[3] Petit C, Batool F, Bugueno IM, et al. Contribution of statins towards periodontal treatment: a review [J]. Mediators Inflamm, 2019, 2019:6367402.
[4] Kellesarian SV, Al Amri MD, Al-Kheraif AA, et al. Efficacy of local and systemic statin delivery on the osseointegration of implants: a systematic review [J]. Int J Oral Maxillofac Implants, 2017, 32(3):497-506.
[5] El-Nabarawi N, El-Wakd M, Salem M. Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study [J]. Drug Des Devel Ther, 2017, 11:1383-1391.
[6] Chuang SC, Chen CH, Fu YC, et al. Estrogen receptor mediates simvastatin-stimulated osteogenic effects in bone marrow mesenchymal stem cells [J]. Biochem Pharmacol, 2015, 98(3):453-464.
[7] Shao PL, Wu SC, Lin ZY, et al. Alpha-5 integrin mediates simvastatin-induced osteogenesis of bone marrow mesenchymal stem cells [J]. Int J Mol Sci, 2019, 20(3):506.
[8] Huang Y, Lin Y, Rong M, et al. 20(S)-hydroxycholesterol and simvastatin synergistically enhance osteogenic differentiation of marrow stromal cells and bone regeneration by initiation of Raf/MEK/ERK signaling [J]. J Mater Sci Mater Med, 2019, 30(8): 87.
[9] Xu R, Shi G, Xu L, et al. Simvastatin improves oral implant osseointegration via enhanced autophagy and osteogenesis of BMSCs and inhibited osteoclast activity [J]. J Tissue Eng Regen Med, 2018, 12(5):1209-1219.
[10] Xu R, Chen J, Cong X, et al. Lovastatin protects mesenchymal stem cells against hypoxia-and serum deprivation-induced apoptosis by activation of PI3K/Akt and ERK1/2 [J]. J Cell Biochem, 2008, 103(1): 256-269.
[11] Yang CN, Kok SH, Wang HW, et al. Simvastatin alleviates bone resorption in apical periodontitis possibly by inhibition of mitophagy-related osteoblast apoptosis [J]. Int Endod J, 2019, 52(5):676-688.
[12] Dolci GS, Portela LV, Onofre de Souza D, et al. Atorvastatin-induced osteoclast inhibition reduces orthodontic relapse [J]. Am J Orthod Dentofacial Orthop, 2017, 151(3):528-538.
[13] Dolci GS, Ballarini A, Gameiro GH, et al. Atorvastatin inhibits osteoclastogenesis and arrests tooth movement [J]. Am J Orthod Dentofacial Orthop, 2018, 153(6):872-882.
[14] Gruber R. Cell biology of osteoimmunology [J]. Wien Med Wochenschr, 2010, 160(17-18):438-445.
[15] Ulivieri C, Baldari CT. Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases [J]. Pharmacol Res, 2014, 88:41-52.
[16] Toledo AON, Couto AMD, Madeira MFM, et al. Cytokines and chemokines associated with Treg/Th17 response in chronic inflammatory periapical disease [J]. Braz Oral Res, 2019, 33:e093.
[17] Shahbaz SK, Sadeghi M, Koushki K, et al. Regulatory T cells: Possible mediators for the anti-inflammatory action of statins [J]. Pharmacol Res, 2019, 149:104469.
[18] Zhang O, Zhang J. Atorvastatin promotes human monocyte differentiation toward alternative M2 macrophages through p38 mitogen-activated protein kinase-dependent peroxisome proliferator-activated receptor γ activation [J]. Int Immunopharmacol, 2015, 26(1):58-64.
[19] Alhamdi JR, Peng T, Al-Naggar IM, et al. Controlled M1-to-M2 transition of aged macrophages by calcium phosphate coatings [J]. Biomaterials, 2019, 196:90-99.
[20] Spiller KL, Anfang RR, Spiller KJ, et al. The role of macrophage phenotype in vascularization of tissue engineering scaffolds [J]. Biomaterials, 2014, 35(15):4477-4488.
[21] Biswas SK, Chittezhath M, Shalova IN, et al. Macrophage polarization and plasticity in health and disease [J]. Immunol Res, 2012, 53(1-3):11-24.
[22] Koch CA, Krabbe S, Hehmke B. Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties? [J]. Rev Endocr Metab Disord, 2018, 19(4):363-395.